Monograph Details
|
|
Endocrine System
> Thyroid disease
|
|
TAPAZOLE |
| Manufacturer |
|
King Pharmaceuticals, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antithyroid. |
| Generic Name |
|
Methimazole 5mg, 10mg; scored tabs. |
| Indications |
|
Hyperthyroidism. |
| Children |
|
Initially 0.4mg/kg daily in 3 divided doses. Maintenance: ½ initial dose. |
| Adults |
|
Initially 15–60mg daily in 3 divided doses, depending on severity of disease. Maintenance: 5–15mg daily. |
| Contraindications |
|
Nursing mothers. |
| Precautions |
|
Discontinue if agranulocytosis, aplastic anemia, exfoliate dermatitis, hepatitis, or elevated liver transaminases (3xULN) occurs. Monitor prothrombin time, WBC, bone marrow function. Pregnancy (Cat.D). |
| Interactions |
|
Potentiates anticoagulants. |
| Adverse Reactions |
|
Rash, GI disturbances, arthralgia, paresthesia, hair and taste loss, agranulocytosis, blood dyscrasias, aplastic anemia, hepatic dysfunction, drug fever, lupus-like syndrome, insulin autoimmune syndrome, periarteritis; nephritis (rare). |
| How Supplied |
|
Tabs—100 |
|
|
|
|
